Trade Roots, a Wareham-based Cannabis dispensary grows cannabis plants for making CBD with THC in their greenhouse, and manufactures CBD products for sale in their shop and distribution to buyers.
John Tlumacki | Boston Globe | Getty Images
Cannabis stocks leapt on Tuesday afternoon, buoyed by a Biden administration decision to ease federal restrictions on marijuana.
The U.S. Drug Enforcement Administration is expected to approve an opinion by the Department of Health and Human Services to reclassify marijuana as a Schedule III substance, NBC News reported, citing four sources with knowledge of the decision.
For more than 50 years, marijuana has been labeled a Schedule I substance, the same category that drugs like methamphetamine and heroin fall into. Drugs in that category are defined as substances with "no currently accepted medical use and a high potential for abuse," according to the DEA.
A move to Schedule III would place marijuana alongside Tylenol with codeine and anabolic steroids – that is, "drugs with a moderate to low potential for physical and psychological dependence."
Investors in cannabis stocks cheered the move, with the AdvisorShares Pure US Cannabis ETF (MSOS) surging nearly 20% in afternoon trading. Amplify U.S. Alternative Harvest ETF (MJUS) jumped about 19%.
MJUS performance 1-day
Individual marijuana stocks with small market capitalizations also rallied. Curaleaf Holdings surged 19% to touch a new 52-week high, while Trulieve Cannabis climbed nearly 30%.
Don’t miss these insights from CNBC PRO
- Money market funds hit another record high — but experts warn it's time to move out of cash. Where they see opportunity
- Morgan Stanley cuts oil forecast, says traders are pricing in a demand slowdown similar to mild recession
- Nvidia may be the AI darling, but it’s time to start looking at this chip stock, one CIO says
- Warren Buffett doesn’t pay attention to macro factors when investing, and here’s why
